Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01PTS
|
|||
| Former ID |
DIB002088
|
|||
| Drug Name |
VG-101
|
|||
| Synonyms |
Seala; VG-101 analogs, Bionovo; Estrogen receptor beta selective agonists (topical intravaginal gel, vaginal dryness), Bionovo; VG-101 (topical intravaginal gel, vaginal dryness), Bionovo
Click to Show/Hide
|
|||
| Indication | Menopause symptom [ICD-11: GA30.0] | Phase 1/2 | [1] | |
| Company |
Bionovo Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Estrogen receptor beta (ESR2) | Target Info | Agonist | [2] |
| KEGG Pathway | Estrogen signaling pathway | |||
| Prolactin signaling pathway | ||||
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | |||
| Validated nuclear estrogen receptor beta network | ||||
| Validated nuclear estrogen receptor alpha network | ||||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Ovarian Infertility Genes | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00453089) VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women. U.S. National Institutes of Health. | |||
| REF 2 | Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.